Papadatou Ioanna, Tzovara Irene, Licciardi Paul V
Immunobiology and Vaccinology Research Laboratory, First Department of Paediatrics, Aghia Sofia Children's Hospital, National and Kapodistrian University of Athens, 111527 Athens, Greece.
Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia.
Vaccines (Basel). 2019 Jan 29;7(1):13. doi: 10.3390/vaccines7010013.
(, pneumococcus) is a major cause of morbidity and mortality worldwide. Achieving long-term immunity against through immunization is an important public health priority. Long-term protection after immunization is thought to rely both on protective serum antibody levels and immunological memory in the form of antigen-specific memory B cells (MBCs). Although the ability to achieve protective antibody levels shortly after pneumococcal vaccination has been well documented for the various infant immunization schedules currently in use worldwide, the examination of immunological memory in the form of antigen-specific MBCs has been much more limited. Such responses are critical for long-term protection against pneumococcal colonization and disease. This review summarizes the published literature on the MBC response to primary or booster immunization with either pneumococcal polysaccharide vaccine (PPV23) or pneumococcal conjugate vaccines (PCVs), aiming to elucidate the immunological mechanisms that determine the magnitude and longevity of vaccine protection against pneumococcus. There is evidence that PCVs induce the production of antigen-specific MBCs, whereas immunization with PPV23 does not result in the formation of MBCs. Increased understanding of the immunological factors that facilitate the induction, maintenance and recall of MBCs in response to pneumococcal vaccination could enable the use of MBC enumeration as novel correlates of protection against . Ongoing studies that examine MBC response to pneumococcal vaccination in high burden settings will be extremely important in our understanding of long-term protection induced by pneumococcal conjugate vaccines.
肺炎球菌是全球发病和死亡的主要原因。通过免疫接种实现对肺炎球菌的长期免疫是一项重要的公共卫生优先事项。免疫接种后的长期保护被认为既依赖于保护性血清抗体水平,也依赖于以抗原特异性记忆B细胞(MBC)形式存在的免疫记忆。尽管目前全球使用的各种婴儿免疫接种计划在肺炎球菌疫苗接种后不久就能达到保护性抗体水平的能力已有充分记录,但对抗原特异性MBC形式的免疫记忆的研究却更为有限。这种反应对于长期预防肺炎球菌定植和疾病至关重要。本综述总结了已发表的关于MBC对肺炎球菌多糖疫苗(PPV23)或肺炎球菌结合疫苗(PCV)初次或加强免疫反应的文献,旨在阐明决定疫苗对肺炎球菌保护的程度和持久性的免疫机制。有证据表明,PCV可诱导抗原特异性MBC的产生,而PPV23免疫接种不会导致MBC的形成。进一步了解促进MBC对肺炎球菌疫苗接种的诱导、维持和回忆的免疫因素,可能使MBC计数作为预防肺炎球菌的新型保护相关指标得以应用。正在高负担环境中研究MBC对肺炎球菌疫苗接种反应的研究,对于我们理解肺炎球菌结合疫苗诱导的长期保护极为重要。